Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Weighted Average and Diluted): 2010-2024

Historic EPS (Weighted Average and Diluted) for China Pharma Holdings (CPHI) over the last 8 years, with Dec 2024 value amounting to -$0.27.

  • China Pharma Holdings' EPS (Weighted Average and Diluted) rose 73.85% to -$0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.41, marking a year-over-year increase of 161.84%. This contributed to the annual value of -$0.27 for FY2024, which is 70.33% up from last year.
  • China Pharma Holdings' EPS (Weighted Average and Diluted) amounted to -$0.27 in FY2024, which was up 70.33% from -$0.91 recorded in FY2023.
  • China Pharma Holdings' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.27 during FY2024, with a 5-year trough of -$0.91 in FY2023.
  • Moreover, its 2-year median value for EPS (Weighted Average and Diluted) was -$0.59 (2023), whereas its average is -$0.59.
  • Data for China Pharma Holdings' EPS (Weighted Average and Diluted) shows a peak YoY spiked of 70.33% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows China Pharma Holdings' EPS (Weighted Average and Diluted) stood at -$0.91 in 2023, then surged by 70.33% to -$0.27 in 2024.